The Fort Worth Press - DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.

USD -
AED 3.672502
AFN 64.497441
ALL 81.976464
AMD 360.939776
ANG 1.790403
AOA 918.00007
ARS 1564.721529
AUD 1.499565
AWG 1.8025
AZN 1.697411
BAM 1.780015
BBD 2.014925
BDT 124.431743
BGN 1.77347
BHD 0.37752
BIF 3005.064869
BMD 1
BND 1.290108
BOB 11.760691
BRL 5.9105
BSD 1.000364
BTN 93.26812
BWP 14.13177
BYN 2.991536
BYR 19600
BZD 2.012105
CAD 1.433145
CDF 2284.999705
CHF 0.84385
CLF 0.025718
CLP 1012.180135
CNY 6.667802
CNH 6.691215
COP 3440.75
CRC 447.852202
CUC 1
CUP 24.010812
CVE 100.354492
CZK 22.261801
DJF 177.719801
DKK 6.808215
DOP 60.22024
DZD 137.111946
EGP 53.815904
ERN 15
ETB 164.207346
EUR 0.91091
FJD 2.285805
FKP 0.76038
GBP 0.763495
GEL 2.590015
GGP 0.76038
GHS 11.760691
GIP 0.76038
GMD 73.499756
GNF 8869.129151
GTQ 7.648344
GYD 209.20879
HKD 7.84164
HNL 26.893165
HRK 6.831965
HTG 131.167832
HUF 340.020145
IDR 18276.65
ILS 3.298955
IMP 0.76038
INR 93.35275
IQD 1516.716647
IRR 1933164.507829
ISK 124.989937
JEP 0.76038
JMD 158.33375
JOD 0.708977
JPY 159.782501
KES 130.05003
KGS 87.450342
KHR 4070.711897
KMF 449.000112
KPW 900.00035
KRW 1332.549698
KWD 0.31195
KYD 0.833781
KZT 450.420933
LAK 22542.082103
LBP 89594.673923
LKR 332.990535
LRD 168.042222
LSL 17.234984
LTL 2.95274
LVL 0.60489
LYD 6.474601
MAD 9.949443
MDL 18.358468
MGA 4516.971636
MKD 56.054128
MMK 2099.801407
MNT 3600.814049
MOP 8.083819
MRU 40.808154
MUR 46.840104
MVR 15.396121
MWK 1734.473816
MXN 19.027215
MYR 4.113013
MZN 63.898376
NAD 17.235689
NGN 1350.904939
NIO 36.812887
NOK 9.768275
NPR 149.256652
NZD 1.81938
OMR 0.384487
PAB 1.000505
PEN 3.413633
PGK 4.500548
PHP 63.860438
PKR 276.538224
PLN 4.04348
PYG 6272.553936
QAR 3.636844
RON 4.872303
RSD 107.170333
RUB 82.176838
RWF 1480.709546
SAR 3.753475
SBD 8.137041
SCR 13.968358
SDG 601.496925
SEK 10.18658
SGD 1.29174
SHP 0.757117
SLE 22.803496
SLL 20969.503664
SOS 571.743216
SRD 37.360015
STD 20697.981008
STN 22.297051
SVC 8.753544
SYP 13002.000337
SZL 17.231478
THB 33.930065
TJS 9.202511
TMT 3.5
TND 3.031431
TOP 2.40776
TRY 50.465025
TTD 6.788623
TWD 33.029506
TZS 2659.984958
UAH 45.068373
UGX 4236.613258
UYU 40.609599
UZS 11985.383457
VES 916.62795
VND 25755
VUV 120.949122
WST 2.823281
XAF 597.517722
XAG 0.022471
XAU 0.000271798586
XCD 2.70255
XCG 1.803049
XDR 0.707052
XOF 597.517722
XPF 108.541031
YER 236.550328
ZAR 17.479706
ZMK 9001.197632
ZMW 20.559821
ZWL 321.999592
SSP 5879.599296
MXV 2.133446
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.
DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.

DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.

CLIA-Certified Cancer Diagnostics Laboratory Will Acquire Spectroscopy Platform to Support Machine Learning Expansion into Additional Cancer Types

  • CE Marks previously held in Europe for breast cancer and colorectal cancer tests
  • Spectroscopy platform to be transferred to Helomics to revalidate data correlations with biopsies and imaging and support LDT launch prior to FDA submissions
  • Issued patents in the U.S. and Europe provide exclusivity into at least 2034

Text size:

TAMPA, FL / ACCESS Newswire / November 19, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMeds AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare technology company that integrates its physical pharmaceutical, laboratory and telemedicine infrastructures with its EinsteinRx™ Healthcare AI technology-powered digital platform, today announced that it has agreed to acquire certain assets from the estate of Todos Medical Ltd., including its Cancer Artificial Intelligence ("Cancer AI") Total Biochemical Infrared Analysis ("TBIA") blood tests for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1), originally developed at Ben Gurion University (BGU) in Israel.

The TBIA Cancer AI blood testing platform leverages Fourier-transform infrared (FTIR) spectroscopy biochemical analysis of blood plasma and peripheral blood mononuclear cell (PBMC) components to distinguish between healthy subjects and patients with cancer.

Because FTIR digitizes the biochemical information contained in a blood sample, the test is designed to multiplex algorithms for multiple different cancer tests and disease states using the same blood draw, allowing for the identification of various types of cancer in blood without the need for antibodies or other biological inputs, helping to improve test scalability and reducing per-test cost of goods sold (COGS). The technology was also previously used to identify and distinguish between viral and bacterial infections. The TBIA Cancer AI blood testing platform is covered by issued U.S. and European patents, providing market exclusivity into at least 2034.with expected terms extending into at least 2034.

"The TBIA Cancer AI blood testing platform is a technology that was ahead of its time and now has the opportunity to truly flourish in the AI era," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "To be able to use a single vial of blood, perform a single data capture experiment in the lab and produce results that can help detect multiple types of cancer from that one blood test is truly transformative. This has the potential to make cancer detection not only less expensive to deploy on a per-cancer-diagnosis basis than existing liquid biopsy and other cancer screening tests, but also more clinically useful because this technology digitizes the immune system and as such may be able to identify and distinguish the body's response to cancer, even at the earliest carcinoma in situ stage. Earlier detection could open the possibility of its use in routine annual blood testing paradigms that would allow patients to be recommended for confirmatory imaging and biopsy testing much earlier in the disease course where cancers are typically significantly more likely to respond to treatment. We look forward to implementing this technology at our Helomics Cancer AI laboratory in Pittsburgh, Penn., where we will work with our emerging oncologist network to source blood samples, under IRB-approved protocols and with patient consent, from patients whose treating physicians are sending in tumor biopsies for the ChemoFx® Assay evaluation, that has been granted two unique CPT codes and has begun to receive coverage decisions, helping us to generate revenue while also generating the necessary data to validate the TBIA Cancer AI blood test to support eventual commercial launch as a Laboratory Developed Test and to advance it through the U.S. Food & Drug Administration (FDA) regulatory process thereafter."

Other assets the Company agreed to acquire include Todos' license to the LymPro™ Alzheimer's diagnostic blood test and 100% of the shares of Todos' wholly-owned subsidiary Todos Medical Singapore PTE Ltd., which previously owned equity in Pathnova Labs PTE Ltd. that was recently exchanged for shares Archerfish Precision Diagnostics Pte Ltd. following Pathnova's merger with Angsana Molecular & Diagnostics Laboratory.

The global cancer diagnostics market size was valued at USD 189.19 Billion in 2024 and is projected to grow to USD 386.19 Billion by 2035, according to Market Research Future.

The agreement to acquire these assets from the estate of Todos Medical is subject to Court Approval. The TBIA tests have not been cleared or approved by the FDA and are not currently commercially available in the United States.

For more information about DataMeds AI or Helomics, please contact James Lambert, Vice President at Rubenstein Public Relations, at [email protected] or at 212-805-3024.

About DataMEDS AI

DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.

About Helomics Corporation

Helomics Corporation, a wholly owned subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania, focused on precision oncology. Its flagship ChemoFx® Assay tests a patient's live tumor cells against a panel of chemotherapy agents to give oncologists patient-specific information to help inform treatment decisions in gynecologic cancers. ChemoFx is billed under CPT codes 81535 and 81536. Through Predictive Oncology, its Innovation division, Helomics combines a large annotated biobank of tumor samples, from over 130 tumor types, with artificial intelligence and multi-omic data. It uses these to help pharmaceutical and biotechnology partners predict tumor response and speed up oncology drug discovery and development. The ChemoFx Assay is a laboratory-developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit https://predictive-oncology.com/ .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the Company's ability to complete the acquisition of the TBIA Cancer AI platform and the other assets from the estate of Todos Medical Ltd., including the satisfaction of closing conditions and the receipt of any required court, liquidator or third-party approvals and consents, and the timing thereof; the Company's ability to obtain good title to, and to transfer to Helomics, the acquired patents, know-how, data, algorithms and equipment; Helomics' ability to revalidate historical data correlations with biopsy and imaging results; Helomics' ability to obtain blood samples from patients through its oncologist network under appropriate patient consents and institutional review board approvals, and to comply with data privacy and security requirements; the ability to develop, validate and commercially launch any TBIA test as a laboratory-developed test, and the timing and cost of doing so; the clinical performance of the TBIA tests, including their sensitivity, specificity, ability to detect early-stage cancers and ability to detect multiple cancer types from a single blood draw, none of which has been established in prospective clinical studies; the ability to obtain clearance or approval from the U.S. Food and Drug Administration, or any other regulatory authorization in the United States, the European Union or elsewhere, for any TBIA test, and changes in the regulation of laboratory-developed tests; the availability of reimbursement from third-party payors and adoption by physicians and patients; the expected cost of goods sold and pricing of the TBIA tests relative to existing liquid biopsy and other cancer screening tests; the scope, validity, enforceability and expiration of the acquired patents, and the Company's ability to protect its intellectual property and to operate without infringing the rights of others; the value of the LymPro™ license, the Company's ability to obtain any licensor consent required for its assignment, and the value of any interest held through Todos Medical Singapore Pte. Ltd.; Helomics' ability to grow ChemoFx® Assay testing volumes, oncologist relationships and reimbursement; competition from other cancer diagnostics companies, including developers of liquid biopsy and multi-cancer early detection tests; the accuracy of third-party market size estimates; and the Company's liquidity, capital resources and ability to fund the integration and development of the acquired assets and its other operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

DataMEDS AI Media Contact

James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | [email protected]

DataMEDS AI Investor Contact

[email protected]

###

SOURCE: DataMEDS AI, Inc.



View the original press release on ACCESS Newswire

B.Martinez--TFWP